1.Determination of Content of Tannins in Cibot Rhizome and Its Differently Processed Samples
Tianzhu JIA ; Xiulan DIAO ; Jun LI ; Shiquan XIE ; Gongyan LI ;
Chinese Traditional Patent Medicine 1992;0(01):-
Objective: It was to investigate the content alteration of the tannins in cibot rhizome and its processed samples. Method: The casein method was used to determine the content of tannins. Results: The content of tannins decreased after the medicinal material was processed. Conclusion: Processing may decrease the content of tannins in cibot rhizome. The raw was better than the other processed samples if the tannins were used as active constituents.
2.Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).
Jianhua SHI ; Ying CHENG ; Qiming WANG ; Kai LI ; Lin WU ; Baohui HAN ; Gongyan CHEN ; Jianxing HE ; Jie WANG ; Haifeng QIN ; Xiaoling LI
Frontiers of Medicine 2022;16(5):766-772
Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing ⩾ two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gammaglutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard.
Humans
;
Lung Neoplasms/drug therapy*
;
Treatment Outcome
;
Neoplasm Recurrence, Local/chemically induced*
;
Quinolines/adverse effects*